Abstract:Colorectal cancer (CRC) is the most common digestive malignancy across the world. Its first-line treatments applied in the routine clinical setting include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. However, resistance to therapy has been identified as the major clinical challenge that fails the treatment method, leading to recurrence and distant metastasis. An increasing number of studies have been attempting to explore the underlying mechanisms of the resistance of CRC cells to different therapies, which can be summarized into two aspects: (1) The intrinsic characters and adapted alterations of CRC cells before and during treatment that regulate the drug metabolism, drug transport, drug target, and the activation of signaling pathways; and (2) the suppressive features of the tumor microenvironment (TME). To combat the issue of therapeutic resistance, effective strategies are warranted with a focus on the restoration of CRC cells' sensitivity to specific treatments as well as reprogramming impressive TME into stimulatory conditions. To date, nanotechnology seems promising with scope for improvement of drug mobility, treatment efficacy, and reduction of systemic toxicity. The instinctive advantages offered by nanomaterials enable the diversity of loading cargoes to increase drug concentration and targeting specificity, as well as offer a platform for trying the combination of different treatments to eventually prevent tumor recurrence, metastasis, and reversion of therapy resistance. The present review intends to summarize the known mechanisms of CRC resistance to chemotherapy, radiotherapy, immunotherapy, and targeted therapy, as well as the process of metastasis. We have also emphasized the recent application of nanomaterials in combating therapeutic resistance and preventing metastasis either by combining with other treatment approaches or alone. In summary, nanomedicine is an emerging technology with potential for CRC treatment; hence, efforts should be devoted to targeting cancer cells for the restoration of therapeutic sensitivity as well as reprogramming the TME. It is believed that the combined strategy will be beneficial to achieve synergistic outcomes contributing to control and management of CRC in the future.

Norcantharidin in cancer therapy – a new approach to overcoming therapeutic resistance: A review

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

Emerging Nano-Based Strategies Against Drug Resistance in Tumor Chemotherapy

Nanodelivery Systems as a Novel Strategy to Overcome Treatment Failure of Cancer

Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials

Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer

Nano-enabled colorectal cancer therapy

A new approach to overcoming resistance to immunotherapy: nanotechnology

A protracted war against cancer drug resistance

Nanomaterials for cancer therapy: current progress and perspectives

Targeted Drug Nanodelivery and Immunotherapy for Combating Tumor Resistance

Drug resistance and combating drug resistance in cancer

Drug Resistance and New Therapies in Colorectal Cancer

Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy

Recent progress in targeted therapy for non-small cell lung cancer

Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer

Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers

Targeting non-coding RNAs to overcome cancer therapy resistance